Oncology PracticeCombo shows promise in HER2-positive breast cancer with brain metsMarch 15, 2019Breast CancerCNS/Brain Cancer
Oncology PracticeFDA approves another trastuzumab biosimilar for HER2-positive breast cancer, gastric cancerMarch 12, 2019Breast Cancer
Oncology PracticeNovel immunostimulant combo shows early efficacyMarch 12, 2019MelanomaImmuno-oncologyBreast CancerSarcoma & GIST
Oncology PracticeAnthracycline-free regimen OK in HER2-negative early breast cancerMarch 4, 2019Breast Cancer
Oncology PracticeFDA Expanded Access benefits heavily pretreated patients, especially childrenMarch 4, 2019Practice ManagementCNS/Brain CancerBreast CancerLung CancerBusiness of Medicine
Oncology PracticeFDA approves subcutaneous trastuzumab for HER2-positive breast cancersFebruary 28, 2019Breast Cancer
Oncology PracticeBreast cancer recurrence lower, survival better with dose-intensified regimensFebruary 12, 2019Breast Cancer
Oncology PracticeTherapy ups breast cancer survivors’ cardiac risksFebruary 7, 2019Breast CancerPatient & Survivor CarePreventive Care
Oncology PracticeClinical relevance of tamoxifen pharmacogenetics in questionFebruary 4, 2019Breast CancerPatient & Survivor Care
Oncology PracticeSingle-cell genomics drive progress toward human breast cell atlas developmentFebruary 1, 2019Breast Cancer
Oncology PracticeAML, myeloma risk higher for breast cancer survivorsJanuary 22, 2019Breast CancerLeukemia, Myelodysplasia, TransplantationAMLMultiple Myeloma
